Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 4/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | DRD5 | P21918 | 3/20 | 0.58 |
| ▸ | HTR7 | P34969 | 6/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13493143 | 0.92 | HTR7 (0.50) | DRD3DRD2DRD5HTR7SIGMAR1 | |
| SCHEMBL13496856 | 0.92 | HTR7 (0.50) | DRD3DRD2DRD5HTR7SIGMAR1 | |
| SCHEMBL13475426 | 0.84 | KCNH2 (0.61) | DRD3DRD2HTR7HTR2A | |
| SCHEMBL11465528 | 0.82 | SIGMAR1 (0.76) | DRD3DRD2HTR7SIGMAR1DRD1 | |
| SCHEMBL11405931 | 0.78 | SIGMAR1 (0.69) | DRD3DRD2DRD5HTR7SIGMAR1 | |
| SCHEMBL9559659 | 0.78 | SIGMAR1 (0.69) | DRD3DRD2DRD5HTR7SIGMAR1 | |
| SCHEMBL6865196 | 0.78 | HTR7 (0.87) | DRD3DRD2DRD5HTR7DRD1 | |
| SCHEMBL7486480 | 0.77 | SIGMAR1 (0.71) | DRD3DRD2DRD5HTR7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7663753 | 0.77 | HTR7 (0.85) | DRD3DRD2DRD5HTR7DRD1 | |
| SCHEMBL1254473 | 0.76 | HTR7 (0.63) | DRD3DRD2DRD5HTR7SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| EP-0998923-A1 | Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | HTR7, HTR1A, HTR6 | DRD3 131/4885DRD2 43/4885DRD5 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.